Effectiveness and toxicity of preoperative therapy in stage iiia non-small cell lung cancer including the memorial sloan-kettering experience with induction mvp in patients with bulky mediastinal lymph node metastases (Clinical n2)

Mark G. Kris, Katherine M W Pisters, Robert J. Ginsberg, James R. Rigas, Vincent A. Miller, Stefan C. Grant, Richard J. Gralla, Robert T. Heelan, Nael Martini

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The use of preoperative chemotherapy with mitomycin, vinblastine and cisplatin (MVP) has led to improved complete resection rates and survival in Stage IIIA non-small cell lung cancer with bulky, ipsilateral, mediastinal lymph node metastases (Clinical N2 disease). The addition of preoperative irradiation has also been explored with results not substantially different from preoperative cisplatin-based chemotherapy alone. While preoperative chemotherapy has been shown to be feasible, the toxicity of both the chemotherapy and the subsequent resection is of concern with an overall treatment-related mortality of nearly 8%. The careful selection of patients, swift management of neutropenia, and meticulous perioperative pulmonary care has the potential to reduce the mortality from multimodality therapy. Having shown survival benefit in multiple single-institution and randomized trials, induction chemotherapy followed by surgery or irradiation is now the treatment of choice for patients with Stage IIIA non-small cell lung cancer with mediastinal lymph node metastases.

Original languageEnglish (US)
JournalLung Cancer
Volume12
Issue numberSUPPL. 1
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Lymph Nodes
Neoplasm Metastasis
Drug Therapy
Cisplatin
Perioperative Care
Induction Chemotherapy
Vinblastine
Mortality
Mitomycin
Therapeutics
Neutropenia
Patient Selection
Survival Rate
Lung
Survival

Keywords

  • Cisplatin
  • Induction chemotherapy
  • Mediastinal lymph node metastases
  • Multimodality therapy
  • Neoadjuvant chemotherapy
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Effectiveness and toxicity of preoperative therapy in stage iiia non-small cell lung cancer including the memorial sloan-kettering experience with induction mvp in patients with bulky mediastinal lymph node metastases (Clinical n2). / Kris, Mark G.; Pisters, Katherine M W; Ginsberg, Robert J.; Rigas, James R.; Miller, Vincent A.; Grant, Stefan C.; Gralla, Richard J.; Heelan, Robert T.; Martini, Nael.

In: Lung Cancer, Vol. 12, No. SUPPL. 1, 1995.

Research output: Contribution to journalArticle

Kris, Mark G. ; Pisters, Katherine M W ; Ginsberg, Robert J. ; Rigas, James R. ; Miller, Vincent A. ; Grant, Stefan C. ; Gralla, Richard J. ; Heelan, Robert T. ; Martini, Nael. / Effectiveness and toxicity of preoperative therapy in stage iiia non-small cell lung cancer including the memorial sloan-kettering experience with induction mvp in patients with bulky mediastinal lymph node metastases (Clinical n2). In: Lung Cancer. 1995 ; Vol. 12, No. SUPPL. 1.
@article{79ec3b91ac614b9c97c6a9a08b3980fd,
title = "Effectiveness and toxicity of preoperative therapy in stage iiia non-small cell lung cancer including the memorial sloan-kettering experience with induction mvp in patients with bulky mediastinal lymph node metastases (Clinical n2)",
abstract = "The use of preoperative chemotherapy with mitomycin, vinblastine and cisplatin (MVP) has led to improved complete resection rates and survival in Stage IIIA non-small cell lung cancer with bulky, ipsilateral, mediastinal lymph node metastases (Clinical N2 disease). The addition of preoperative irradiation has also been explored with results not substantially different from preoperative cisplatin-based chemotherapy alone. While preoperative chemotherapy has been shown to be feasible, the toxicity of both the chemotherapy and the subsequent resection is of concern with an overall treatment-related mortality of nearly 8{\%}. The careful selection of patients, swift management of neutropenia, and meticulous perioperative pulmonary care has the potential to reduce the mortality from multimodality therapy. Having shown survival benefit in multiple single-institution and randomized trials, induction chemotherapy followed by surgery or irradiation is now the treatment of choice for patients with Stage IIIA non-small cell lung cancer with mediastinal lymph node metastases.",
keywords = "Cisplatin, Induction chemotherapy, Mediastinal lymph node metastases, Multimodality therapy, Neoadjuvant chemotherapy, Non-small cell lung cancer",
author = "Kris, {Mark G.} and Pisters, {Katherine M W} and Ginsberg, {Robert J.} and Rigas, {James R.} and Miller, {Vincent A.} and Grant, {Stefan C.} and Gralla, {Richard J.} and Heelan, {Robert T.} and Nael Martini",
year = "1995",
doi = "10.1016/0169-5002(95)00420-6",
language = "English (US)",
volume = "12",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Effectiveness and toxicity of preoperative therapy in stage iiia non-small cell lung cancer including the memorial sloan-kettering experience with induction mvp in patients with bulky mediastinal lymph node metastases (Clinical n2)

AU - Kris, Mark G.

AU - Pisters, Katherine M W

AU - Ginsberg, Robert J.

AU - Rigas, James R.

AU - Miller, Vincent A.

AU - Grant, Stefan C.

AU - Gralla, Richard J.

AU - Heelan, Robert T.

AU - Martini, Nael

PY - 1995

Y1 - 1995

N2 - The use of preoperative chemotherapy with mitomycin, vinblastine and cisplatin (MVP) has led to improved complete resection rates and survival in Stage IIIA non-small cell lung cancer with bulky, ipsilateral, mediastinal lymph node metastases (Clinical N2 disease). The addition of preoperative irradiation has also been explored with results not substantially different from preoperative cisplatin-based chemotherapy alone. While preoperative chemotherapy has been shown to be feasible, the toxicity of both the chemotherapy and the subsequent resection is of concern with an overall treatment-related mortality of nearly 8%. The careful selection of patients, swift management of neutropenia, and meticulous perioperative pulmonary care has the potential to reduce the mortality from multimodality therapy. Having shown survival benefit in multiple single-institution and randomized trials, induction chemotherapy followed by surgery or irradiation is now the treatment of choice for patients with Stage IIIA non-small cell lung cancer with mediastinal lymph node metastases.

AB - The use of preoperative chemotherapy with mitomycin, vinblastine and cisplatin (MVP) has led to improved complete resection rates and survival in Stage IIIA non-small cell lung cancer with bulky, ipsilateral, mediastinal lymph node metastases (Clinical N2 disease). The addition of preoperative irradiation has also been explored with results not substantially different from preoperative cisplatin-based chemotherapy alone. While preoperative chemotherapy has been shown to be feasible, the toxicity of both the chemotherapy and the subsequent resection is of concern with an overall treatment-related mortality of nearly 8%. The careful selection of patients, swift management of neutropenia, and meticulous perioperative pulmonary care has the potential to reduce the mortality from multimodality therapy. Having shown survival benefit in multiple single-institution and randomized trials, induction chemotherapy followed by surgery or irradiation is now the treatment of choice for patients with Stage IIIA non-small cell lung cancer with mediastinal lymph node metastases.

KW - Cisplatin

KW - Induction chemotherapy

KW - Mediastinal lymph node metastases

KW - Multimodality therapy

KW - Neoadjuvant chemotherapy

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0029016819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029016819&partnerID=8YFLogxK

U2 - 10.1016/0169-5002(95)00420-6

DO - 10.1016/0169-5002(95)00420-6

M3 - Article

VL - 12

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - SUPPL. 1

ER -